MAPT and amyloidosis: Among proposed plasma biomarkers, recent evidence suggests that plasma phosphorylated tau (p‐tau)217 is able to accurately identify biological AD, comparable to CSF biomarkers, and most accurately classify amyloid and tau status compared to other plasma markers.5, 6